期刊文献+

多西他赛与调强适形放疗同步治疗食管癌临床疗效观察 被引量:3

下载PDF
导出
摘要 目的探讨调强适形放射治疗联合多西他赛化疗对食管癌的临床疗效。方法对64例食管癌患者根据不同的治疗方法分为两组:单纯放射治疗组(单放组)和放射治疗同步化疗组(放化疗组)。单放组32例,采用调强适形放射治疗,总剂量60~70Gy/6~7周;放化疗组32例,放疗方法及剂量同单放组,化疗采用多西他赛40mg/次,1次/周,共用4~6周,与放疗同步进行。两组均随访3年。结果临床疗效放化疗组优于单放组,两组有显著差异(P<0.05)。单放组:CR9/32(28.1%),PR12/32(37.5%),有效率(CR+PR)65.6%;放化疗组:CR12/32(37.5%),PR16/32(50.0%),有效率(CR+PR)87.5%;1、3年生存率分别为58%和81%、27%和39%。两组差异有显著性(P<0.05)。结论多西他赛与调强适形放疗同步治疗食管癌疗效较好,不良反应可以耐受。
出处 《齐齐哈尔医学院学报》 2011年第1期24-25,共2页 Journal of Qiqihar Medical University
  • 相关文献

参考文献9

  • 1肖泽芬.食管癌[A].见:谷铣之,殷蔚伯,余子豪,等.肿瘤放射治疗学[M].北京:中国协和医科大学出版社,2008:547-572.
  • 2Cooper TD,Brewster AE, Borlery A,et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow -up of a prospective randomized trial (RTOG85 - 01). Radiation Therapy Oncology Group[J]. JAMA, 1999,281 (17) :1 623 - 1 627.
  • 3仇红艳.同期放化疗综合治疗食管癌临床疗效观察[J].实用癌症杂志,2005,20(5):527-528. 被引量:24
  • 4季斌,蔡晶,马煌如,谢国栋,王成.化疗加放射治疗食管癌的前瞻性研究[J].中华放射肿瘤学杂志,2002,11(1):12-14. 被引量:61
  • 5毕益明,付艳,刘百百,陈兴秀,陈秀芳,李全奎,杨金山,王淑燕.食管癌三维适形放疗联合多西它塞同期化疗的临床研究[J].现代肿瘤医学,2007,15(11):1607-1608. 被引量:4
  • 6徐兵河.实用肿瘤内科学[M].北京:人民卫生出版社,2003.34—37.
  • 7Pasini F, de Manzoni G, Pedrazzani C, et al. High pathological response rate in locally advanced esophageal cancer after neoad- juvant combined modality therapy: dose finding of a chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy[J]. Ann Oncol,2005,16(7) : 1 133-1 139.
  • 8Kim ES, Khuri FR. Docetaxel and radiation as combined-modality therapy [ J ]. Oncology( Williston Park), 2002, 16 ( Suppl 6) : 97-105.
  • 9李国忠,张绍华,张志,王瑞林.每周一次多西他赛同步放射治疗食管癌临床疗效观察[J].中国肿瘤临床,2007,34(13):754-757. 被引量:7

二级参考文献24

共引文献94

同被引文献49

  • 1吴剑,戴慧,翁欣然,林权冰,卢晓红.小剂量顺铂对中晚期食管癌放疗增敏作用的近期疗效观察[J].中国肿瘤临床,2006,33(13):768-770. 被引量:34
  • 2吴泰相,刘关键.隐蔽分组(分配隐藏)和盲法的概念、实施与报告[J].中国循证医学杂志,2007,7(3):222-225. 被引量:174
  • 3李国忠,张绍华,张志,王瑞林.每周一次多西他赛同步放射治疗食管癌临床疗效观察[J].中国肿瘤临床,2007,34(13):754-757. 被引量:7
  • 4Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 Suppl 8: S4-S66.
  • 5Hennequin C. [Association of taxanes and radiotherapy: preclinical and clinical studies]. Cancer Radiother 2004; 8 Suppl 1: S95-S105.
  • 6Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg 2004; 198: 205-211.
  • 7Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version. West Sussex: John Wiley & Sons Ltd, 2008.
  • 8Chen Y, Pandya K, Keng PP, Feins R, Raubertas R, Smudzin T, Rosenblatt J, Okunieff P. Schedule-dependent pulsed paclitaxel radiosensitization for thoracic malignancy. Am J Clin Oncol 2001; 24: 432-437.
  • 9Pasini F, de Manzoni G, Pedrazzani C, Grandinetti A, Durante E, Gabbani M, Tomezzoli A, Griso C, Guglielmi A, Pelosi G, Maluta S, Cetto GL, Cordiano C. High pathological response rate in locally advanced esophageal cancer after neoadju- vant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted ve- nous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Onco12005; 16:1133-1139.
  • 10Kim ES, Khuri FR. Docetaxel and radiation as combined-modality therapy. Oncology (Williston Park) 2002; 16: 97-105 .

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部